Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
Journal of Korean Medical Science
; : 188-192, 2006.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-79366
Responsible library:
WPRO
ABSTRACT
This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinipristin-dalfopristin against seven hetero-VISA strains and two methicillin-resistant S. aureus strains were evaluated by the time-kill assay. The combinations of arbekacin with vancomycin, teicoplanin, or ampicillinsulbactam showed the synergistic interaction against hetero-VISA strains. Data suggest that these arbekacin-based combination regimens may be useful candidates for treatment options of hetero-VISA infections.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Staphylococcal Infections
/
Staphylococcus aureus
/
Dibekacin
/
Vancomycin
/
Microbial Sensitivity Tests
/
Sulbactam
/
Methicillin Resistance
/
Virginiamycin
/
Teicoplanin
/
Drug Resistance, Bacterial
Limits:
Humans
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2006
Document type:
Article